Clinical Trial Update: Nivolumab Plus Ipilimumab in Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of nivolumab and ipilimumab in thyroid cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-05-21